Retinoid X Receptor as a Therapeutic Target to Treat Neurological Disorders Associated with α-Synucleinopathy.

Cells · 2025 · PMC12109830 · PMID 40422188

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

not yet significantno p-value reported

In these experiments, the ratio of αS in the injected versus uninjected mouse SNpc was measured at 4 weeks post-injection, a time point when neurodegeneration was not yet significant.

also in 316 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.